Unlock stock picks and a broker-level newsfeed that powers Wall Street.
KOSDAQ - Delayed Quote KRW

Daihan Pharmaceutical Co.,Ltd. (023910.KQ)

Compare
25,450.00
+50.00
+(0.20%)
At close: April 4 at 3:30:30 PM GMT+9
Loading Chart for 023910.KQ
  • Previous Close 25,400.00
  • Open 25,400.00
  • Bid 25,350.00 x --
  • Ask 25,400.00 x --
  • Day's Range 25,200.00 - 25,550.00
  • 52 Week Range 23,750.00 - 29,350.00
  • Volume 5,478
  • Avg. Volume 6,750
  • Market Cap (intraday) 149.646B
  • Beta (5Y Monthly) 0.17
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield 900.00 (3.54%)
  • Ex-Dividend Date Dec 27, 2024
  • 1y Target Est 40,000.00

Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.

www.daihan.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 023910.KQ

View More

Performance Overview: 023910.KQ

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

023910.KQ
2.86%
KOSPI Composite Index (^KS11)
2.75%

1-Year Return

023910.KQ
6.95%
KOSPI Composite Index (^KS11)
10.09%

3-Year Return

023910.KQ
7.59%
KOSPI Composite Index (^KS11)
10.61%

5-Year Return

023910.KQ
0.89%
KOSPI Composite Index (^KS11)
42.89%

Compare To: 023910.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 023910.KQ

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    149.65B

  • Enterprise Value

    72.44B

  • Trailing P/E

    4.43

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.73

  • Price/Book (mrq)

    0.54

  • Enterprise Value/Revenue

    0.35

  • Enterprise Value/EBITDA

    1.46

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.53%

  • Return on Assets (ttm)

    7.69%

  • Return on Equity (ttm)

    12.89%

  • Revenue (ttm)

    204.19B

  • Net Income Avi to Common (ttm)

    33.76B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    77.24B

  • Total Debt/Equity (mrq)

    0.01%

  • Levered Free Cash Flow (ttm)

    12.01B

Research Analysis: 023910.KQ

View More

Company Insights: 023910.KQ

Research Reports: 023910.KQ

View More

People Also Watch